HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
40 hedge funds and large institutions have $20.9M invested in HOOKIPA Pharma in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 13 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 7
123% more call options, than puts
Call options by funds: $89K | Put options by funds: $40K
0.75% less ownership
Funds ownership: 4.4% → 3.65% (-0.75%)
15% less funds holding
Funds holding: 47 → 40 (-7)
18% less capital invested
Capital invested by funds: $25.5M → $20.9M (-$4.69M)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$890K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$94.9K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$86.3K |
| 4 |
Renaissance Technologies
New York
|
+$66.4K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$796K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$378K |
| 3 |
BlackRock
New York
|
-$131K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$102K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$83.8K |
HOOK Hedge Fund Activity: Q2 2024 in Review
40 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q2 2024, worth a combined $20.9M — down 18% from $25.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HOOK and 6 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 16 added.
The largest buyer was EcoR1 Capital, adding an estimated $890K. The largest seller was Morgan Stanley, cutting an estimated $796K.
- 40 institutional investors held HOOKIPA Pharma (HOOK) as of Q2 2024, down from 47 in Q1 2024.
- Funds reported $20.9M of HOOKIPA Pharma stock for Q2 2024, down 18% quarter-over-quarter.
- 6 funds opened new HOOKIPA Pharma positions in Q2 2024 and 13 closed out, a net change of -7 holders.
- The largest HOOKIPA Pharma buyer in Q2 2024 was EcoR1 Capital, an estimated $890K added.
- The largest HOOKIPA Pharma seller in Q2 2024 was Morgan Stanley, an estimated $796K sold.
Based on aggregated 13F filings for Q2 2024.